oxazoles has been researched along with Cognition Disorders in 7 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 1 (14.29) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 1 (14.29) | 29.6817 |
| 2010's | 5 (71.43) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Beier, F; Bérubé, NG; Edwards, M; Jiang, Y; Li, JR; Shin-ya, K; Solomon, LA; Watson, LA | 1 |
| Muller, WJ | 1 |
| Bergis, OE; Black, MD; Boulay, D; Defex, H; Desvignes, C; Featherstone, R; Griebel, G; Kongsamut, S; Kosley, R; Naimoli, V; Pichat, P; Potestio, L; Sahni, S; Sher, R; Slowinski, F; Varty, GB; Vigé, X | 1 |
| Atienzar, F; Célanire, S; Christophe, B; Delannois, F; Delaunoy, C; Delporte, ML; Denonne, F; Durieu, V; Gillard, M; Lallemand, B; Lamberty, Y; Lorent, G; Provins, L; Van Houtvin, N; Vanbellinghen, A; Verbois, V | 1 |
| Bronk, BS; Bryce, DK; Coe, JW; Cook, KK; Duplantier, AJ; Evrard, E; Hajós, M; Hoffmann, WE; Hurst, RS; Maklad, N; Mather, RJ; McLean, S; Nedza, FM; O'Donnell, CJ; O'Neill, BT; Peng, L; Qian, W; Rogers, BN; Rottas, MM; Sands, SB; Schmidt, AW; Shrikhande, AV; Spracklin, DK; Wong, DF; Zhang, A; Zhang, L | 1 |
| Fujio, M; Hashimoto, K; Horikawa, T; Katayama, J; Kuriyama, M; Maeda, J; Murozono, T; Numata, A; Satoh, H; Shiigi, Y; Takanashi, S; Tanaka, H; Tatsumi, R | 1 |
| Eisenhauer, E; Maksymiuk, A; Maroun, JA; Pater, J; Stewart, DJ; Young, V | 1 |
1 review(s) available for oxazoles and Cognition Disorders
| Article | Year |
|---|---|
Treatment of perinatal viral infections to improve neurologic outcomes.
Topics: Acyclovir; Antiviral Agents; Brain; Cognition; Cognition Disorders; Encephalitis, Herpes Simplex; Enterovirus Infections; Female; Ganciclovir; HIV Infections; Humans; Infant, Newborn; Nervous System Diseases; Oxadiazoles; Oxazoles; Pregnancy; Valganciclovir; Virus Diseases | 2017 |
6 other study(ies) available for oxazoles and Cognition Disorders
| Article | Year |
|---|---|
Atrx deficiency induces telomere dysfunction, endocrine defects, and reduced life span.
Topics: Aging; Animals; Bone and Bones; Brain; Cognition Disorders; DNA Damage; DNA Helicases; Female; Fibroblasts; G-Quadruplexes; Genotype; Heterochromatin; Insulin-Like Growth Factor I; Ligands; Longevity; Male; Mice; Mice, Transgenic; Microscopy, Fluorescence; Nuclear Proteins; Oxazoles; Phenotype; Stem Cells; Telomere; Thyroxine; X-linked Nuclear Protein | 2013 |
The mGluR2 positive allosteric modulator, SAR218645, improves memory and attention deficits in translational models of cognitive symptoms associated with schizophrenia.
Topics: Allosteric Site; Amphetamines; Animals; Attention; Calcium; Cerebral Cortex; Cognition; Cognition Disorders; Cyclic AMP; Dizocilpine Maleate; Electroconvulsive Therapy; HEK293 Cells; Humans; Indans; Male; Maze Learning; Memory; Memory, Short-Term; Mice; Mice, Inbred C57BL; Mice, Transgenic; Oxazoles; Phenotype; Pyrimidines; Rats; Rats, Sprague-Dawley; Receptors, AMPA; Schizophrenia | 2016 |
Phenyl-oxazoles, a new family of inverse agonists at the H(3) histamine receptor.
Topics: Animals; Benzene; Caco-2 Cells; Cell Line; Cognition Disorders; Drug Inverse Agonism; Histamine Antagonists; Humans; Male; Mice; Microsomes, Liver; Oxazoles; Pyrrolidines; Rats; Rats, Sprague-Dawley; Receptors, Histamine H3; Structure-Activity Relationship; Thiazoles | 2010 |
Discovery of 4-(5-methyloxazolo[4,5-b]pyridin-2-yl)-1,4-diazabicyclo[3.2.2]nonane (CP-810,123), a novel alpha 7 nicotinic acetylcholine receptor agonist for the treatment of cognitive disorders in schizophrenia: synthesis, SAR development, and in vivo eff
Topics: alpha7 Nicotinic Acetylcholine Receptor; Animals; Azabicyclo Compounds; Biological Availability; Cells, Cultured; Cognition Disorders; Epithelial Cells; Female; Hippocampus; Humans; Kidney; Microsomes, Liver; Nicotinic Agonists; Nootropic Agents; Oocytes; Oxazoles; Rats; Receptors, Nicotinic; Schizophrenia; Skin; Structure-Activity Relationship; Xenopus laevis | 2010 |
(R)-3'-(3-methylbenzo[b]thiophen-5-yl)spiro[1-azabicyclo[2,2,2]octane-3,5'-oxazolidin]-2'-one, a novel and potent alpha7 nicotinic acetylcholine receptor partial agonist displays cognitive enhancing properties.
Topics: alpha7 Nicotinic Acetylcholine Receptor; Animals; Biological Availability; Cerebral Cortex; Cognition; Cognition Disorders; Dopamine; Evoked Potentials, Auditory; Haplorhini; Hippocampus; In Vitro Techniques; Male; Maze Learning; Membrane Potentials; Neurons; Nicotinic Agonists; Nootropic Agents; Oxazoles; Patch-Clamp Techniques; Quinuclidines; Radioligand Assay; Rats; Rats, Wistar; Receptors, Nicotinic; Stereoisomerism; Structure-Activity Relationship | 2006 |
Phase II study of acivicin in non-small cell lung cancer: a National Cancer Institute of Canada Study.
Topics: Adult; Aged; Antibiotics, Antineoplastic; Canada; Carcinoma, Non-Small-Cell Lung; Cognition Disorders; Drug Evaluation; Female; Hematologic Diseases; Humans; Isoxazoles; Lung Neoplasms; Male; Middle Aged; Oxazoles | 1986 |